-
JAKKS Pacific, Inc. (NASDAQ: JAKK) shares tumbled
30.5 percent to $4.90. Piper Jaffray downgraded Jakks Pacific from Overweight to Neutral, while BMO Capital downgraded Jakks
Pacific to Market Perform.
-
Voltari Corp (NASDAQ: VLTC) shares fell 20.4
percent to $2.15. Voltari shares have dropped 47.88 percent over the past 52 weeks, while the S&P 500 index has gained
11.72 percent in the same period.
- Medgenics Inc (NASDAQ: GNMX) shares dropped 15.3 percent to $5.80 after climbing 22.98 percent on Friday.
-
Ambac Financial Group, Inc. (NASDAQ: AMBC) shares
dipped 14.5 percent to $22.24. MKM Partners downgraded Ambac Financial from Neutral to Sell.
-
Wins Finance Holdings Inc (NASDAQ: WINS) shares
slipped 10.2 percent to $146.00. Wins Finance shares have jumped 1,245.24 percent over the past 52 weeks, while the S&P 500
index has gained 11.72 percent in the same period.
-
Evoke Pharma Inc (NASDAQ: EVOK) shares fell 7.7
percent to $1.91.
-
Euroseas Ltd. (NASDAQ: ESEA) declined 7.2 percent
to $2.12. Euroseas shares have dropped 18.86 percent over the past 52 weeks, while the S&P 500 index has gained 11.72
percent in the same period.
-
Deutsche Bank AG (USA) (NYSE: DB) dropped 4 percent
to $18.25. Citigroup downgraded Deutsche Bank from Neutral to Sell.
-
ArcelorMittal SA (ADR) (NYSE: MT) shares fell 3
percent to $7.43. UBS downgraded Arcelor Mittal to sell.
-
Innospec Inc. (NASDAQ: IOSP) slipped 2.8 percent
to $69.10. Monness Crespi Hardt downgraded Innospec from Buy to Neutral.
-
Yamana Gold Inc. (USA) (NYSE: AUY) fell 2.7 percent
to $2.57. BMO Capital downgraded Goldcorp from Outperform to Market Perform.
-
Acorda Therapeutics Inc (NASDAQ: ACOR) declined
2.4 percent to $19.62. Janney Capital initiated coverage on Acorda Therapeutics with a Neutral rating.
Latest Ratings for JAKK
Date |
Firm |
Action |
From |
To |
Dec 2016 |
PiperJaffray |
Downgrades |
Overweight |
Neutral |
Dec 2016 |
BMO Capital |
Downgrades |
Outperform |
Market Perform |
Oct 2015 |
BMO Capital |
Upgrades |
Market Perform |
Outperform |
View More Analyst Ratings for
JAKK
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.